Organisation paid for research Program year 2025 Source: CMS Open Payments

Chesapeake Urology Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$479,227

78 payments

Through program year 2025, Chesapeake Urology Associates LLC is reported as receiving $479,227 in research payments, across 78 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$105,612	13
2024	Research	$45,050	4
2023	Research	$217,454	40
2022	Research	$109,954	18
2021	Research	$1,157	3

Breakdown

Who paid Research payments · program years 2021–2025

Veru Inc. $280,675 45 payments
Dendreon Pharmaceuticals LLC $197,396 30 payments
Bayer HealthCare Pharmaceuticals Inc. $1,157 3 payments

Studies the money was for Research payments · program years 2021–2025

Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $117,411 19 payments
ProvONE Study $89,350 11 payments
ProvONE $61,212 5 payments
Efficacy Evaluation of Veru-111 for McRpc in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (Veracity) $60,115 10 payments
A Phase 1B/2 Study to Evaluate the Safety and Tolerability of Veru-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer $56,719 9 payments
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $46,834 14 payments
To Evaluate Safety and Tolerability of Veru-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer $24,190 3 payments
Veru_V2010001_3914_01 $22,240 4 payments
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) $1,157 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.